Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fulcrum Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fulcrum Therapeutics's regulatory disclosures and financial reporting.
BlackRock, Inc. filed Amendment No. 4 reporting its beneficial ownership of common stock of THERAPEUTICS INC (symbol FULC). BlackRock reports beneficial ownership of 4,802,880 shares of common stock, representing 7.2% of the class.
BlackRock has sole voting powersole dispositive power
Kevin Tang and affiliated Tang Capital entities, as 10% owners of Fulcrum Therapeutics, reported indirect open-market purchases totaling 167,616 shares of common stock on July 16–17, 2026. Reported weighted-average prices were $3.56 and $3.52 per share, with trade ranges from $3.46 to $3.60. These shares are held through Tang Capital funds, and the trades were not reported under a Rule 10b5-1 trading plan.
BlackRock Portfolio Management LLC reported a passive ownership stake in THERAPEUTICS INC common stock on a Schedule 13G. The firm disclosed beneficial ownership of 4,021,379 shares, representing 6.0% of the outstanding common stock as of June 30, 2026.
BlackRock Portfolio Management LLC has sole voting power over 3,604,410 shares and sole dispositive power over 4,021,379 shares, with no shared voting or dispositive power. The shares are held on behalf of various underlying persons who may receive dividends or sale proceeds; according to the disclosure, no single such person holds more than five percent of the issuer’s outstanding common shares.
Tang Capital Management, LLC and related investment entities report beneficial ownership of 6,913,329 shares of Fulcrum Therapeutics, Inc. common stock, representing 10.4% of the class based on 66,633,321 shares outstanding as of April 20, 2026. All reported shares are held with shared voting and dispositive power, with no sole voting or dispositive authority for any filer.
Within this aggregate position, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. respectively report shared power over 1,630,142, 2,160,423, 1,630,127 and 1,492,637 shares, all under the oversight of Kevin Tang.
Investment entities associated with Kevin Tang and Tang Capital Management LLC, each a ten percent owner of Fulcrum Therapeutics, Inc., reported open-market purchases of 249,946 shares of common stock from July 13–15, 2026 at prices ranging from $3.50 to $3.60 per share. Reported prices are weighted averages for multiple trades within these ranges.
Following these transactions, the reporting group’s indirect beneficial ownership increased to 6,913,329 shares, held across Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc., in which Kevin Tang has a pecuniary interest.
Fulcrum Therapeutics, Inc. reports that investment funds affiliated with Tang Capital beneficially own 6,663,383 shares of common stock, held indirectly. Kevin Tang and Tang Capital Management LLC are each identified as ten percent owners, with Kevin Tang having a pecuniary interest through several Tang Capital entities.
Fulcrum Therapeutics director Sonja Banks received a new stock option grant. The award covers 32,000 shares of common stock at an exercise price of $3.66 per share and expires on June 29, 2036. All shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant date, subject to continued service.
Fulcrum Therapeutics director Katina Dorton received a new stock option award covering 32,000 shares of Common Stock. The option carries an exercise price of $3.66 per share and expires on June 29, 2036. It was granted at no upfront cost and is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or earlier, immediately before the first annual stockholder meeting after the grant date, subject to continued service. Following this grant, Dorton holds 32,000 stock options directly from this award.
Fulcrum Therapeutics director Robert J. Gould received a stock option grant for 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036. It was granted as compensation, not through an open-market transaction.
According to the terms, all 32,000 shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual meeting of stockholders after that date, as long as Gould continues to serve the company. Following this grant, his reported option holdings from this filing total 32,000 shares.
Fulcrum Therapeutics director Kate Haviland received a new stock option grant. She was awarded options covering 32,000 shares of Fulcrum Therapeutics common stock at an exercise price of $3.6600 per share.
The option was granted as of June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, assuming continued service. Following this grant, she holds options for 32,000 shares directly.